Nomura downgrades Hartalega stock to Neutral amid pricing pressures

Nomura/Instinet downgraded Hartalega (KLSE:HART) from Buy to Neutral, significantly reducing its price target to MYR1.31 from MYR2.64. This action is driven by ongoing pricing pressure in non-US markets and uncertainty surrounding average selling price recovery in the US, prompting substantial cuts to earnings per share forecasts for FY26-FY28. While the revised target implies a 1% downside, Hartalega's net assets per share of MYR1.27 are expected to limit further weakness, with potential US tariffs on Chinese gloves identified as a key upside risk for Malaysian manufacturers.

Analysis

Nomura/Instinet has downgraded Hartalega (KLSE:HART) to Neutral from Buy, reflecting a significant deterioration in the company's outlook. The price target was slashed from MYR2.64 to MYR1.31, implying a 1% downside from current levels. This revision is predicated on persistent pricing pressure in non-US markets and ambiguity surrounding the recovery of average selling prices in the US. Consequently, Nomura has cut its earnings per share estimates for Hartalega by 40% for FY26, 28% for FY27, and 20% for FY28. The valuation basis has also been compressed, with the target price-to-earnings multiple for FY26 reduced from 33x to 27x. While the near-term prospects are challenged, the report suggests a potential floor for the stock price, noting that Hartalega's net assets per share of MYR1.27 should limit further downside. A key upside risk remains the potential implementation of US tariffs on Chinese gloves, which could improve market dynamics for Malaysian manufacturers.

Key Decisions for Investors

• Given the significant earnings forecast reductions and the downgrade to Neutral, investors should reassess their bullish thesis on Hartalega as the near-term growth outlook has materially weakened.
• Consider the stock's current risk-reward profile, where downside may be cushioned by the net asset value of MYR1.27 per share, but upside appears limited by ongoing pricing pressures.
• Closely monitor US trade policy for any developments on tariffs against Chinese gloves, as this is identified as the primary potential catalyst that could positively alter the company's earnings trajectory.
• Evaluate the revised valuation of 27.3x FY26 estimated earnings, noting that this multiple reflects lowered growth expectations and persistent sector-wide uncertainty.